NASDAQ · Biotechnology

GNPX (GNPX) Stock

$5.99 -1.16% NASDAQ: GNPX Healthcare

Valuation

MetricValue
Price$5.99
Market Cap$3.02M
P/E Ratio-0.03
P/B Ratio0.26
P/S Ratio0.00
EPS (TTM)$-17.40
52-Week High$55.00
52-Week Low$0.42
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-160.84%
ROA-76.19%
ROCE-200.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-21.0M$-24.0M$-31.0M$-21.0M$-16.0M
Net Profit$-21.0M$-24.0M$-31.0M$-21.0M$-16.0M
EPS$-877.50$-990.00$-1128.00$-266.95$-17.40
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$43.0M$25.0M$11.0M$4.0M$10.0M
Total Liabilities$2.0M$3.0M$3.0M$3.0M$2.0M
Cash$39.0M$21.0M$7.0M$2.0M$8.0M
Borrowings$0$0$0$0$0

Latest News

Genprex’s Reqorsa combo secures Canadian patent for lung cancer Pharmaceutical Technology · Jun 23, 2026 Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer PR Newswire · Jun 22, 2026 Genprex to Participate at BIO International Convention 2026 PR Newswire · Jun 17, 2026 Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting PR Newswire · May 26, 2026 Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting PR Newswire · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-18.0M$-25.0M$-17.0M$-15.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$277.0M$0
Net Cash Flow$11.0M$-18.0M$-14.0M$-5.0M$6.0M
Free Cash Flow$-14.0M$-18.0M$-25.0M$-17.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-1774.24%
Quick Ratio5.61
Interest Coverage-16.00
Return 1Y-96.69%
Return 3Y-99.97%
Return 5Y-99.99%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BDRXBiodexa Pharmaceuticals Plc $1.71 -3.39% 0.00 $1.28M 0.00%
BIVI $1.52 +6.29% -0.11 $11.46M 0.00%
CEROCERo Therapeutics Holdings, Inc. $0.01 -7.69% 0.00 $14464 0.00%
CMMBChemomab Therapeutics Ltd. $1.43 -2.72% -1.30 $8.80M 0.00%
CNSP $5.40 +0.75% -0.14 $3.10M 0.00%

About GNPX

GNPX is led by CEO Ryan Confer, employs 15 people, headquartered in US, publicly traded since 2018.

GNPX stock trades at $5.99 with a market capitalization of $3.02M. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of 0.26, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.42 and $55.00, and currently trades 89.1% below its 52-week high.

On profitability, GNPX generates a return on equity (ROE) of -160.84%, return on capital employed of -200.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides